Thomas Benekos
Overview
Explore the profile of Thomas Benekos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
15
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tsili A, Benekos T, Argyropoulou M
Acta Radiol
. 2024 May;
65(5):513-519.
PMID: 38720456
The Ancient Greeks were great innovators in all academic fields, including medicine. Hippocrates of Kos, the Father of Medicine, established many terms for the genitourinary (GU) system, such as nephros,...
2.
Margariti P, Benekos T
Radiol Case Rep
. 2023 Mar;
18(5):1784-1787.
PMID: 36923389
Juvenile xanthogranuloma (JX) is a non-Langerhans cell histiocytosis. Although precipitating factors remain unclear, it has been described mainly in infancy and early childhood. The giant variant of JX is a...
3.
Rallis D, Balomenou F, Drougia A, Benekos T, Vlahos A, Tzoufi M, et al.
Minerva Pediatr (Torino)
. 2021 Apr;
76(3):328-334.
PMID: 33845562
Background: Evidence examining the association of over-hydration during early life with hemodynamically significant patent ductus arteriosus (hsPDA) and other morbidities is limited. Our aim was to evaluate the association of...
4.
Kosmeri C, Milionis H, Vlahos A, Benekos T, Bairaktari E, Cholevas V, et al.
J Clin Lipidol
. 2021 Jan;
15(2):292-300.
PMID: 33478934
Background: Dyslipidemia has been associated with endothelial dysfunction in childhood. Impairment of renal function has been demonstrated in dyslipidemic adults. Objective: The aim of this study was to assess markers...
5.
Benekos T, Kosmeri C, Vlahos A, Milionis H
J Pediatr Endocrinol Metab
. 2020 Feb;
33(4):533-538.
PMID: 32084003
Background To assess the efficacy and safety of lipid-lowering treatment in children with heterozygous familial hypercholesterolemia (HeFH) aged ≤12 years attending a tertiary hospital-based outpatient lipid clinic. Methods Data in...